 |
Julia Karow tracks trends in next-generation sequencing for research and clinical applications for GenomeWeb's In Sequence and Clinical Sequencing News. E-mail Julia Karow or follow her GenomeWeb Twitter accounts at @InSequence and @ClinSeqNews. |
In Pilot, Team at Thomas Jefferson University Tests 454 GS Junior for Cancer Mutational Profiling
May 16, 2012
In Pilot, Team at Thomas Jefferson University Tests 454 GS Junior for Cancer Mutational Profiling
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Thomas Jefferson University and VelaDx to Develop NGS-Based Tests for Oncology, Infectious Disease
February 6, 2013 / Clinical Sequencing News - VelaDx, Thomas Jefferson Co-developing MDx for Cancer, Infectious Diseases
January 30, 2013 / GenomeWeb Daily News - Study Finds Roche's NGS-Based HIV Assay Comparable to TruGene; Company Expects 2014 CE-IVD Approval
January 30, 2013 / Clinical Sequencing News - IRON-II Study Uses 454 Sequencing to Investigate New Markers for Hematological Malignancies
September 12, 2012 / Clinical Sequencing News - Roche and Spanish Collaborators to use 454 to Study Hepatitis Drug Resistance
April 12, 2011 / Clinical Sequencing News